ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ONMD
MXCT (34) BIAF (29) ISPC (30) NRC (67) ⌘ Pro Terminal β†’

OneMedNet Corp (Class A) (ONMD) β€” RQD Stock Rating Cockpit

$4.28 +1.42% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.28

OneMedNet Corp (Class A) (ONMD) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $25.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ONMD Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ONMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, OneMedNet Corp (Class A) (NASDAQ: ONMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $4.28 (+1.42% 1D, market cap $25.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ONMD ranks #917 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ONMD compare to MXCT and BIAF in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ONMD carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MXCT (MaxCyte Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -27.1%, cap $164.1M) and BIAF (bioAffinity Technologies Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ONMD?
β–Ό

Per ONMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001849380), OneMedNet Corp (Class A) generated $1.4M in revenue (+111.4% YoY), -$2.8M in net income, and -$7.5M in free cash flow against $2.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.28 (+0.07%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (26/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510026
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (4)Whales (3)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.5% Base Target
$24 Bull$4 Base$3 Bear
πŸ“¬ FREE ONMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ONMD)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
πŸ” WHY ONMD SCORES 26/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (31% of score)

FRED Regime Γ— Technicals: 3% of 52W Range β€’ RSI-14 at 38.8 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
18
Grade E$4.02+18.2% Next Q
Q2 (-2Q)
21
Grade E$4.75-7.4% Next Q
Q3 (-1Q)
23
Grade E$4.40-2.7% Next Q
Current
26
Grade E$4.28-10.5% Hist 90D Ξ±
Trajectory: E (18) β†’ E (26)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ONMD Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ONMD currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.49) and Max Pain ($4.49) forces dealer call-delta covering toward $24.15.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ONMDβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œONMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
38.830 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE3% OF RANGE
L: $4$4.28H: $23
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on ONMD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-35.0% ROIC with -30.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (23)

6/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like ONMD
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ONMD)

  • βœ“Walkthrough of ONMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ONMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.24%β–Ό DESCENDING CHANNEL
2026-11-03O $4.37H $4.37L $4.22C $4.28VOL 61.1K
RES: $7.43SUP: $2.58SMA50: $5.49SMA200: $7.16
$12.15$9.83$7.52$5.21$2.89RES $7.43SUP $2.58$4.282026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ONMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ONMD Butterfly Map β†’ + Track ONMD β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +111.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ONMD today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ONMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ONMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ONMD)

Health Care Rank #917 of 1015 βš”οΈ MXCT vs ONMD Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ONMD vs. MXCT, BIAF, ISPC, NRC)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, OneMedNet Corp (Class A) (ONMD) ranks #917 by composite RQD confidence (26/100, grade E) and #816 by equity capitalization ($25.4M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and β€” gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ONMD at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ONMD ACTIVE
OneMedNet Corp (Class A)
E 26/100 β€” -30.0% -35.0% +1.42% $25.4M Benchmark Subject
MXCT
MaxCyte Inc.
E 34/100 β€” 96.0% -27.1% -8.80% $164.1M /mxct-vs-onmd β†’
BIAF
bioAffinity Technologies Inc.
E 29/100 β€” β€” -35.0% +2.75% $3.7M /biaf-vs-onmd β†’
ISPC
iSpecimen Inc.
E 30/100 β€” 11.2% -35.0% +0.82% $2.1M /ispc-vs-onmd β†’
NRC
NRC Health
C+ 67/100 44.8x β€” 21.0% +1.80% $527.1M /nrc-vs-onmd β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001849380 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OneMedNet Corp (Class A) (ONMD) reported GAAP revenue of $1.4M (+111.4% vs. FY2024 revenue of $643.0K , and +33.1% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of -$7.5M, and free cash flow of -$7.5M (-7.3% YoY). On the balance sheet, ONMD closed FY2025 with $2.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.4M -$2.8M -$7.5M -$7.5M $2.2M β€”
FY2024 (FY) 2024-12-31 $643.0K -$10.1M -$7.0M -$7.0M $3.7M β€”
FY2023 (FY) 2023-12-31 $1.0M -$33.8M -$4.8M -$4.8M β€” β€”

3. ONMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ONMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, OneMedNet Corp (Class A) (NASDAQ: ONMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $4.28 (+1.42% 1D, market cap $25.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ONMD ranks #917 in composite RQD confidence.

How does ONMD compare to MXCT and BIAF in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ONMD carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MXCT (MaxCyte Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -27.1%, cap $164.1M) and BIAF (bioAffinity Technologies Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ONMD?

Per ONMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001849380), OneMedNet Corp (Class A) generated $1.4M in revenue (+111.4% YoY), -$2.8M in net income, and -$7.5M in free cash flow against $2.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ONMD trading relative to its 50-day, 200-day, and 52-week technical levels?

ONMD last traded at $4.28 (+1.42% on volume of 8,972 shares), positioning the stock -22.04% below its 50-day simple moving average ($5.49) and -40.22% below its 200-day simple moving average ($7.16). Across its 52-week range of $3.61 to $23.00, ONMD sits at the 3.5% percentile with a 14-day RSI of 38.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($3.74 to $4.82).

Direct Sub-Reports: ONMD RQD Cockpit ONMD 12M Forecast ONMD Earnings & Move ONMD Dividends & DRIP ONMD Insiders & 13F ONMD Whale Options ONMD Profit Sankey ONMD News & Why
ROARABLE RATING BRIEF β€’ RQD 26/100 (E) βœ“ SEC XBRL & RQD VERIFIED

ONMD β€” OneMedNet Corp (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

OneMedNet Corp (Class A) (ONMD) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.28 (+1.42% 1D, market capitalization $25.4M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

β€” The profile confirms the sector as Health Care and the industry as Biotechnology: Commercial Physical & Biological Resarch, listed on NASDAQ, with a market capitalization of $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OneMedNet Corp (Class A) (ONMD) reported $1.4M in annual revenue (up from $643.0K in FY2024, +111.4% YoY) and -$2.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.0M revenue, -$33.8M net income) through FY2025, ONMD scaled operating cash flow to -$7.5M and free cash flow to -$7.5M, backed by $2.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.61 – $23.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks therefore cannot be mapped from the source data. The only sector-level context available is the Health Care classification and a Beta of 1.0.

  • Key Question #1: Can ONMD sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.4M and free cash flow of -$7.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ONMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ONMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OneMedNet Corp (Class A) (ONMD) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ONMD Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ONMD Bull vs. Bear Conversation Board β€” What's Your Call at $4.28?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ONMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ONMD:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $5.19 (+23.0%)
πŸ“Œ Pinned Debate

A new partner will distribute OneMedNet's de-identified U.S. medical data to drug companies worldwide, a GREEN-flagged catalyst that co

The street is overcomplicating OneMedNet Corp (Class A) (ONMD). A new partner will distribute OneMedNet's de-identified U.S. medical data to drug companies worldwide, a GREEN-flagged catalyst that could open a revenue channel.. With an RQD score of 26/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $4.56.

CapAlloc_Nerd πŸ‚ BULL

@MidwestValue Agree on the RQD 26/100 quality, though with 1.0 beta I'm scaling in with half-size at $4.22 and keeping dry powder in case we test $3.92.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $3.17 (-24.9%)
Spot @ $4.22

A -35% ROIC, negative FCF across three reported years, and an RQD score of 26 (Grade E) signal that the business is not currently self-

Careful chasing ONMD at $4.22. A -35% ROIC, negative FCF across three reported years, and an RQD score of 26 (Grade E) signal that the business is not currently self-funding.. Gross margin is -30.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.17 on multiple compression.

LIVE TAPE